SMC does not recommend abatacept (Orencia®) for treatment of juvenile idiopathic artritis due to non-submission

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

SMC does not recommend abatacept (Orencia®) for treatment of juvenile idiopathic artritis due to non-submission

Source: Scottish Medicines Consortium (SMC)

Date published: 10/05/2010 15:53

Summary

by: Hina Radia

In the absence of a submission from the holder of the marketing authorisation holder, the Scottish Medicines Consortium (SMC) does not recommend the use of abatacept (Orencia®) within NHSScotland for the treatment of juvenile idiopathic arthritis.

About this library entry

Category: 10.1.3 Drugs that suppress the rheumatic disease process | Adolescents (11-18 years) | Drug reviews | Rheumatology | Scottish Medicines Consortium

NeLM area: Evidence > Drug Specific Reviews

Link

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.

Printer Friendly Version

Related evidence

10.1.3 Drugs that suppress the rheumatic disease process

01/05/2012

AWMSG issues Final Appraisal Recommendation on use of adalimumab (Humira®) for active polyarticular juvenile idiopathic arthritis

10/04/2012

SMC does not accept tocilizumab for moderate to severe rheumatoid arthritis in patients unresponsive/ intolerant to DMARDs or TNF antagonists.

10/04/2012

SMC does not accept belimumab (Benlysta®) as add on therapy for SLE

Adolescents (11-18 years)

15/12/2010

NICE issues clinical guideline on sedation for diagnostic and therapeutic procedures in children and young people

27/10/2010

NICE issues guidance on the management of nocturnal enuresis (CG 111)

10/05/2010

SMC does not recommend abatacept (Orencia®) for treatment of juvenile idiopathic artritis due to non-submission

Rheumatology

15/05/2012

SMC accepts etanercept (Enbrel®) for restricted use in children and adolescents with polyarticular JIA

15/05/2012

SMC accepts collagenase (Xiapex®) for restricted use in the treatment of Dupuytren’s contracture

01/05/2012

AWMSG issues Final Appraisal Recommendation on use of adalimumab (Humira®) for active polyarticular juvenile idiopathic arthritis

Back